Recent Updates
Recently added Catalysts
BHST Positive Sentiment Score: 70/100

MATERIAL CHANGE REPORT Material Change Report FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 . Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Street Vancouver, BC, V6C 2T6 (the "Company" or "BioH

Key Takeaway: BioHarvest Sciences Inc. has announced its intention to conduct an underwritten public offering of 2,485,000 shares of common stock at a price of $7.00 per share. The offering is expected to generate approximately $17.4 million in gross proceeds, which will be utilized for various corporate purposes, including research and development and debt refinancing. The company has granted underwriters a 30-day option to purchase additional shares, and the offering is anticipated to close around November 10, 2025, subject to customary conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioHarvest plans to raise approximately $17.4 million through a public offering.
  • The offering includes a 30-day option for underwriters to purchase additional shares, indicating confidence in demand.
  • Funds from the offering are intended for research, development, and expansion of business operations.

CONCERNS & RISKS

  • The offering is reliant on customary conditions being met for closure.
  • The market reaction to the stock sale and its impact on share price is uncertain.

Full Press Release Details

MATERIAL CHANGE REPORT
Item 1.Name and Address of Company
BIOHARVEST SCIENCES INC.
Suite 1140 - 625 Howe Street
Vancouver, BC, V6C 2T6
(the "Company" or "BioHarvest")
Item 2.Date of Material Change
The news releases (the "News Releases", each a "News Release") were issued on November 6, 2025 and November 7, 2025 and disseminated by Newsfile Corp.
Item 4.Summary of Material Change
On November 6, 2025, the Company announced its intention to offer and sell shares of its common stock in an underwritten public offering.
On November 7, 2025, the Company announced the pricing of an underwritten public offering of 2,485,000 shares of common stock, no par value, and at a public offering price of $7.00 per share. BioHarvest expects the gross proceeds from this offering to be approximately $17.4 million, before deducting the underwriting discount and other offering expenses. In connection with the offering, BioHarvest has granted the underwriters a 30-day option to purchase up to 372,750 additional shares of its common stock at the public offering price, less the underwriting discount. BioHarvest expects to close the offering, subject to the satisfaction of customary conditions, on or about November 10, 2025.
Craig-Hallum is acting as the sole managing underwriter for the offering.
BioHarvest expects to use the net proceeds of the offering for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or debt refinancing, capital expenditures, and general corporate purposes, including funding working capital.
The offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-289908), as amended, including a base prospectus, relating to the shares of common stock to be issued in the proposed offering was initially filed with the Securities and Exchange Commission (the "SEC") on August 28, 2025 and was declared effective on September 8, 2025. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
The Company is furnishing a 5.1 Opinion pursuant to Item 601(b)(5) of Regulation S-K under the Securities Act of 1933.
Item 5.Full Description of Material Change
A full description of the material change is set out in detail in the copies of the news releases filed under the Company's Profile on sedarplus.ca.
A copy of the underwriting agreement is attached hereto as Schedule "A".
A copy of the November 6, 2025 news release is attached hereto as Schedule "B".
A copy of the November 7, 2025 news release is attached hereto as Schedule "C".
A copy of the 5.1 Opinion is attached hereto as Schedule "D".
Item 6.Reliance on Subsection 7.1(2) of National Instrument 51-102
Item 7.Omitted Information
Item 8.Executive Officer
For further information, please contact:
Secretary and VP, Investor Relations
Item 9.Date of Report
MATERIAL CHANGE REPORT
Underwriting Agreement
MATERIAL CHANGE REPORT
News Release, dated November 6, 2025
MATERIAL CHANGE REPORT
News Release, dated November 7, 2025
MATERIAL CHANGE REPORT

Frequently Asked Questions

What did BioHarvest announce on November 6, 2025?

BioHarvest announced plans to offer and sell shares of its common stock.

How many shares were priced on November 7, 2025?

An underwritten public offering of 2,485,000 shares was priced at $7.00 each.

What is the expected gross proceeds from the offering?

The offering is expected to generate approximately $17.4 million.

Who is the sole managing underwriter for the offering?

Craig-Hallum is the sole managing underwriter for BioHarvest's offering.

What will the proceeds from the offering be used for?

Proceeds will support research, development, and general corporate purposes.

Last updated: Nov 7, 2025